<DOC>
	<DOCNO>NCT01917552</DOCNO>
	<brief_summary>multi-center , prospective , randomize , open-label phase III</brief_summary>
	<brief_title>Adjuvant Capecitabine Versus Observation Alone Curatively Resected Stage IB Gastric Cancer</brief_title>
	<detailed_description>This prospective , randomize , open-label phase III study adjuvant chemotherapy curative resection patient pathologic stage IB ( AJCC 6th edition ) gastric cancer least one additional risk factor ( additional risk factor recurrence include age &gt; 65 year , male gender , presence lymphovascular invasion , presence perineural invasion ) . The superiority design compare efficacy safety profile adjuvant capecitabine ( Arm A ) versus observation alone ( Arm B ) .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Curatively resect gastric gastroesophageal junction adenocarcinoma Pathologic stage IB ( AJCC 6th edition ) least one additional risk factor recurrence ( additional risk factor recurrence include age &gt; 65 year , male gender , presence lymphovascular invasion , presence perineural invasion ) . Age : 18 74years ECOG performance status : 02 Adequate bone marrow function ( ANC &gt; 1,500/uL , Platelets 100,000/uL , Hb &gt; 8.0 g/dL ) Adequate renal function ( serum creatinine &lt; 1.5 mg/dL ) Adequate hepatic function ( bilirubin &lt; 1.5 mg/dL , ALT AST &lt; 3 time upper limit normal ) Written informed consent Pregnant lactate woman . Women childbearing potential either positive pregnancy test baseline . Postmenopausal woman must amenorrheic least 12 month consider nonchild bear potential . Sexually active male female ( childbearing potential ) unwilling practice contraception study medication 3 month discontinuation study medication . Any evidence metastatic disease ( include presence tumor cell ascites ) . Previous chemotherapy radiotherapy currently treat gastric cancer . No recovery serious complication gastrectomy . History another malignancy within last five year except cure basal cell carcinoma skin cure carcinoma insitu uterine cervix . History uncontrolled seizure , central nervous system disorder psychiatric disability judge investigator clinically significant precluding inform consent interfere compliance oral drug intake . Clinically significant ( i.e . active ) cardiac disease : e.g . unstable angina , symptomatic coronary artery disease , New York Heart Association ( NYHA ) grade II great congestive heart failure serious cardiac arrhythmia require medication myocardial infarction within last 6 month . Lack physical integrity upper gastrointestinal tract malabsorption syndrome likely influence absorption capecitabine , inability take oral medication . Serious uncontrolled intercurrent infection serious uncontrolled concomitant disease . Organ allograft require immunosuppressive therapy . Received investigational drug agent/procedure , i.e . participation another trial within 4 week randomization . Requirement concurrent use antiviral agent sorivudine ( antiviral ) chemically related analogue , brivudine . Positive serologic test HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Gastric adenocarcinoma , gastroesophageal junction adenocarcinoma , adjuvant , capecitabine , gastric cancer , stage 1b</keyword>
</DOC>